Combined Treatment with Anticancer Vaccine Using Genetically Modified Endothelial Cells and Imatinib in Bladder Cancer

PURPOSE: We sought to maximize the antitumor effect of an anticancer vaccine based on genetically modified endothelial cells by combining it with the platelet-derived growth factor receptor inhibitor imatinib. MATERIALS AND METHODS: Human umbilical vein endothelial cells (HUVECs) were infected with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Seung Beom, Park, Yong Hyun, Lee, Eunhye, Ku, Ja Hyeon, Kim, Hyeon Hoe, Kwak, Cheol
Formato: Texto
Lenguaje:English
Publicado: The Korean Urological Association 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106165/
https://www.ncbi.nlm.nih.gov/pubmed/21687392
http://dx.doi.org/10.4111/kju.2011.52.5.327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106165/
https://www.ncbi.nlm.nih.gov/pubmed/21687392
http://dx.doi.org/10.4111/kju.2011.52.5.327

Ejemplares similares